Discontinuation of imatinib in Belgian patients with chronic myeloid leukaemia

Mineur, P; Doyen, Chantal; Straetemans, N; Van Eygen, K; Pranger, D; Bosly, André; André, Marc; Devos, T; Knoops, L

Discontinuation of imatinib in Belgian patients with chronic myeloid leukaemia

Mineur, P

;

Doyen, Chantal

;

Straetemans, N

;

Van Eygen, K

;

Knoops, L

;et.al.

(2016) Belgian Journal of Hematology — Vol. 7, n° 5, p. 184-187 (2016)

Files

MineurPBelJHematol2016.pdf

Restricted Access
Adobe PDF
1.56 MB

Request a copy

Details

Authors

Mineur, P
Author
Doyen, ChantalUCLouvain
Author
Straetemans, N
Author
Van Eygen, K
Author
Bosly, AndréUCLouvain
Author
André, MarcUCLouvain
Author
Knoops, L
Author

Affiliations

UCLouvainSSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie
UCLouvain(MGD) Service d'hématologie
UCLouvainSSS/IREC/MONT - Pôle Mont Godinne

Citations

APA
Chicago
FWB

Mineur, P., Doyen, C., Straetemans, N., Van Eygen, K., Pranger, D., Bosly, A., André, M., Devos, T., & Knoops, L. (2016). Discontinuation of imatinib in Belgian patients with chronic myeloid leukaemia. Belgian Journal of Hematology, 7(5), 184-187. https://hdl.handle.net/2078.5/89002 (Original work published 2016)